Indication & Dosage |
|
|
Oral |
TREATMENT OF PERIPHERAL VASCULAR DISORDERS |
Adult:
As modified-release formulation: 400 mg tid (normally for at least 8 weeks), reduce to 400 mg bid if adverse effects occur. Adjust dose in patients with impaired renal function or severe hepatic impairment. |
|
|
|
Administration |
Should be taken with food. |
|
|
Precautions |
Ischaemic heart disease, hypotension. Adjust dosage in patients concomitantly on antihypertensives and hypoglycaemic agents. Impaired renal or liver function. Start at lower dose in elderly; safety and efficacy not established in children; tablets should not be chewed, crushed or broken. |
|
|
Potentially Life-threatening
Adverse Drug Reactions |
Nausea, vomiting, dizziness, headache, flushing; angina, palpitations; occasional cardiac arrhythmias; hepatitis, jaundice; blood dyscrasias reported; agitation; sleep disturbances; hypotension; thrombocytopenia; intrahepatic cholestasis. |
|
|
Adverse Drug Reactions |
Fatal haemorrhage (cerebral and GIT); anaphylactoid reaction. |
|
|
Interactions |
May potentiate antihypertensives. Increased bleeding with ketorolac and meloxicam. High parenteral doses may enhance hypoglycaemic action of insulins in diabetic patients. Increase theophylline-serum levels. Delays rate but not extent of absorption (serum levels may decrease if taken with food); administer with meals to minimise GI effects. |
|
|